JP2020506943A - 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用 - Google Patents

養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用 Download PDF

Info

Publication number
JP2020506943A
JP2020506943A JP2019542453A JP2019542453A JP2020506943A JP 2020506943 A JP2020506943 A JP 2020506943A JP 2019542453 A JP2019542453 A JP 2019542453A JP 2019542453 A JP2019542453 A JP 2019542453A JP 2020506943 A JP2020506943 A JP 2020506943A
Authority
JP
Japan
Prior art keywords
hla
combination
antigen
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019542453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506943A5 (enExample
Inventor
リチャード ジョン オライリー，
リチャード ジョン オライリー，
スーザン エリザベス プロコップ，
スーザン エリザベス プロコップ，
エカテリーナ ドウブロヴィナ，
エカテリーナ ドウブロヴィナ，
パラストー バーラミ ダヒ，
パラストー バーラミ ダヒ，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2020506943A publication Critical patent/JP2020506943A/ja
Publication of JP2020506943A5 publication Critical patent/JP2020506943A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
JP2019542453A 2017-02-07 2018-02-06 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用 Pending JP2020506943A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455860P 2017-02-07 2017-02-07
US62/455,860 2017-02-07
PCT/US2018/016995 WO2018148183A1 (en) 2017-02-07 2018-02-06 Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy

Publications (2)

Publication Number Publication Date
JP2020506943A true JP2020506943A (ja) 2020-03-05
JP2020506943A5 JP2020506943A5 (enExample) 2021-02-25

Family

ID=61274340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542453A Pending JP2020506943A (ja) 2017-02-07 2018-02-06 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用

Country Status (6)

Country Link
US (1) US20200017586A1 (enExample)
EP (1) EP3579846A1 (enExample)
JP (1) JP2020506943A (enExample)
AU (1) AU2018218221A1 (enExample)
CA (1) CA3051869A1 (enExample)
WO (1) WO2018148183A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
SG11202112506SA (en) 2019-05-10 2021-12-30 Univ California Modified pluripotent cells
WO2021009510A1 (en) * 2019-07-16 2021-01-21 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
CN119183385A (zh) * 2022-04-13 2024-12-24 加利福尼亚大学董事会 免疫检查点接合子对免疫细胞的抑制

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073550A1 (en) * 2014-11-05 2016-05-12 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
JP2016540042A (ja) * 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ720288A (en) * 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
CN102282265B (zh) * 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CA2982266A1 (en) * 2015-04-27 2016-11-03 Nicholas MCGRANAHAN Method for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540042A (ja) * 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
WO2016073550A1 (en) * 2014-11-05 2016-05-12 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy

Also Published As

Publication number Publication date
AU2018218221A1 (en) 2019-08-15
CA3051869A1 (en) 2018-08-16
US20200017586A1 (en) 2020-01-16
EP3579846A1 (en) 2019-12-18
WO2018148183A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
KR102395528B1 (ko) 입양 세포 치료를 위한 t 세포주 및 이의 도너를 선택하는 방법
Derré et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
US20230220097A1 (en) Treatment and prevention of cancer using virus-specific immune cells expressing chimeric antigen receptors
US10857182B2 (en) Generation and use in adoptive immunotherapy of stem cell-like memory T cells
CN112969470A (zh) 用于扩增抗原特异性car-t细胞、组合物的方法及其相关用途
JP2020506943A (ja) 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用
Khalaf et al. In vitro generation of cytotoxic T cells with potential for adoptive tumor immunotherapy of multiple myeloma
US20210000874A1 (en) Methods of selecting t cell line for adoptive cellular therapy
WO2017156365A1 (en) Methods of generating antigen-specific t cells for adoptive immunotherapy
Meckiff Evolution of the human CD4+ T cell response to Epstein-Barr virus infection-analysis of systemic and local immune responses
HK1242211B (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
HK1242211A1 (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221122